Michael J. Rybak

37.0k citations

426 papers · 27.2k indexed · 7 hit papers · h-index 76

Impact in

Clinical Biochemistry top 0.01%
- Bacterial Identification and Susceptibility Testing
Applied Microbiology and Biotechnology top 0.02%

Papers in

Clinical Biochemistry 163
- Bacterial Identification and Susceptibility Testing 163
Molecular Medicine 116
- Antibiotic Resistance in Bacteria 116

Co-authors: Donald P. Levine Arnold S. Bayer Glenn W. Kaatz Catherine Liu Sara E. Cosgrove Barbara E. Murray David A. Talan Scott K. Fridkin
Journals: Antimicrobial Agents and Chemotherapy (149 papers)Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (50 papers)Open Forum Infectious Diseases (32 papers)Journal of Antimicrobial Chemotherapy (26 papers)Infectious Diseases and Therapy (22 papers)
Partner nations: United States Colombia Spain

In The Last Decade

Michael J. Rybak

419 papers receiving 26.3k citations

Hit Papers

7 papers align trajectories log scale

Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists 2020 · 702 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 American Journal of Health-System Pharmacy
2015 Circulation
2011 Clinical Infectious Diseases
2011 Clinical Infectious Diseases
2009 Clinical Infectious Diseases
2008 American Journal of Health-System Pharmacy
2005 Clinical Infectious Diseases

Peers

Countries citing papers authored by Michael J. Rybak

Since Specialization

Citations

This map shows the geographic impact of Michael J. Rybak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Rybak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Rybak more than expected).

Fields of papers citing papers by Michael J. Rybak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Rybak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Rybak. The network helps show where Michael J. Rybak may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael J. Rybak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael J. Rybak Line = papers co-authored together Michael J. Rybak links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Antibiotic stewardship in the emergency department setting: Focus on oral antibiotic selection for adults with skin and soft tissue infections American Journal of Health-System Pharmacy ·Omar Youssef Abdallah AboHamed, Michael J. Rybak, Kerry L. LaPlante, Thomas P. Lodise, George Sakoulas, Muriel Burk, Francesca Cunningham	2024	1
2	Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in Acinetobacter baumannii Antibiotics ·Jacinda C. Abdul‐Mutakabbir, Iván Eichhardt, Christina Athanasiades, Peter Jorth, Victor Nizet, Hansel M. Fletcher, Keith S. Kaye, Michael J. Rybak	2024	2
3	1033. Unexpected Allies: Vancomycin and Cefazolin Combination Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia Open Forum Infectious Diseases ·Diego Martínez Delgado, Ashlan J. Kunz Coyne, Michael J. Rybak	2023	0
4	Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pseudomonas aeruginosa Pneumonia for Patients Who Are Morbidly Obese Open Forum Infectious Diseases ·Ashlan J. Kunz Coyne, Chung Ki Dong, Michael P. Veve, Michael J. Rybak	2023	1
5	High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production Open Forum Infectious Diseases ·Ashlan J. Kunz Coyne, Amer El Ghali, Huang Jiang, P. S. DELGOBO, Nicholas Rebold, Dana Holger, Michael P. Veve, Michael J. Rybak	2023	15
6	Evaluation of Omadacycline Alone and in Combination with Rifampin against Staphylococcus aureus and Staphylococcus epidermidis in an In Vitro Pharmacokinetic/Pharmacodynamic Biofilm Model Antimicrobial Agents and Chemotherapy ·Taylor Morrisette, Kyle Stamper, Katherine L. Lev, Razieh Kebriaei, Dana Holger, Jacinda C. Abdul‐Mutakabbir, Ashlan J. Kunz Coyne, Michael J. Rybak	2023	4
7	Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro : Bacteriophage-Antibiotic Combination Microbiology Spectrum ·Razieh Kebriaei, Katherine L. Lev, Renad Alotaibi, Kyle Stamper, Dana Holger, Taylor Morrisette, Ashlan J. Kunz Coyne, Susan M. Lehman, Michael J. Rybak	2022	31
8	Exebacase in Addition to Daptomycin against MRSA Antimicrobial Agents and Chemotherapy ·Razieh Kebriaei, Kyle Stamper, Katherine L. Lev, Taylor Morrisette, Jacinda C. Abdul‐Mutakabbir, Raymond Schuch, Dario Lehoux, Michael J. Rybak	2021	7
9	In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Antibiotics ·Jacinda C. Abdul‐Mutakabbir, Juwon Yim, Jean E Schore, Caroline Boyd, Kyle Stamper, Mehulee Sarkar, Razieh Kebriaei, Ryan K. Shields, Mariana Castanheira, Keith S. Kaye, Michael J. Rybak	2021	24
10	Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists American Journal of Health-System Pharmacy ·Michael J. Rybak, Jennifer Lê, Thomas P. Lodise, Donald P. Levine, John S. Bradley, Catherine Liu, Bruce A. Mueller, Manjunath P. Pai, Annie Wong‐Beringer, John C. Rotschafer, Keith A. Rodvold, Holly Maples, Fateme Amiri Simkoii Hit paper breakdown →	2020	702
11	Bacteriophage-Antibiotic Combinations for Enterococcus faecium with Varying Bacteriophage and Daptomycin Susceptibilities Antimicrobial Agents and Chemotherapy ·Taylor Morrisette, Katherine L. Lev, Razieh Kebriaei, Jacinda C. Abdul‐Mutakabbir, Kyle Stamper, Sandra Morales, Susan M. Lehman, С. Шермухамедов, Breck A. Duerkop, César A. Arias, Michael J. Rybak	2020	32
12	A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli European Journal of Clinical Microbiology & Infectious Diseases ·Taylor Morrisette, Abdalhamid M Lagnf, Sara Alosaimy, Michael J. Rybak	2020	11
13	Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments Open Forum Infectious Diseases ·Erin K McCreary, Ravina Kullar, Matthew Geriak, Evan J Zasowski, Alexander Boden, Lucas Schulz, M. Strähle, Guangrui Xie, Fadi Haddad, Michael J. Rybak, Marcus Zervos, George Sakoulas, Warren E. Rose	2019	65
14	Daptomycin Plus β-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study Clinical Infectious Diseases ·Sarah C J Jorgensen, Evan J Zasowski, Trang D Trinh, Abdalhamid M Lagnf, Sahil Bhatia, Noor Sabagha, Jacinda C. Abdul‐Mutakabbir, Sara Alosaimy, Ryan P. Mynatt, Susan L. Davis, Michael J. Rybak	2019	72
15	Bacteriophage Therapeutics: A Primer for Clinicians on Phage‐Antibiotic Combinations Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Taylor Morrisette, Razieh Kebriaei, Katherine L. Lev, Sandra Morales, Michael J. Rybak	2019	75
16	Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model Antimicrobial Agents and Chemotherapy ·Jonghoon Jay Kim, Brian J. Werth, Poochit Nonejuie, John P. McRoberts, Joe Pogliano, George Sakoulas, Juwon Yim, María Esperanza Balaguera Álvarez, Michael J. Rybak	2016	33
17	β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium Journal of Antimicrobial Chemotherapy ·Jordan R. Smith, Katie E. Barber, 奥野洋史, Minhua Fan, George Sakoulas, Michael J. Rybak	2015	100
18	Novel Daptomycin Combinations against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations Antimicrobial Agents and Chemotherapy ·Molly E. Steed, Céline Vidaillac, Michael J. Rybak	2010	47
19	Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006 Antimicrobial Agents and Chemotherapy ·Hélio S. Sader, Paul D. Fey, Douglas N. Fish, Ajit P. Limaye, George A. Pankey, James J. Rahal, Michael J. Rybak, David R. Snydman, Lisa L. Steed, Ken B. Waites, Ronald N. Jones	2009	107
20	Teicoplanin vs vancomycin: cost-effectiveness comparisons. PubMed ·Michael J. Rybak	1993	8

About Michael J. Rybak

Michael J. Rybak is a scholar working on Clinical Biochemistry, Molecular Medicine, Applied Microbiology and Biotechnology, Infectious Diseases and Pharmacology, having authored 426 papers that have together received 27.2k indexed citations. Recurring topics across this work include Antimicrobial Resistance in Staphylococcus (298 papers), Antibiotics Pharmacokinetics and Efficacy (189 papers), Bacterial Identification and Susceptibility Testing (163 papers), Antibiotic Resistance in Bacteria (116 papers), Infective Endocarditis Diagnosis and Management (57 papers), Streptococcal Infections and Treatments (52 papers), Pneumonia and Respiratory Infections (51 papers) and Bacterial biofilms and quorum sensing (36 papers). The work is most often cited by research in Clinical Biochemistry (9.8k citations), Applied Microbiology and Biotechnology (2.1k citations), Infectious Diseases (17.4k citations), Molecular Medicine (4.6k citations) and Pharmacology (9.5k citations). Michael J. Rybak has collaborated with scholars based in United States, Colombia and Spain. Frequent co-authors include Donald P. Levine, Arnold S. Bayer, Glenn W. Kaatz, Catherine Liu, Sara E. Cosgrove, Barbara E. Murray, David A. Talan, Scott K. Fridkin, Adolf W. Karchmer and Henry F. Chambers. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, Open Forum Infectious Diseases, Journal of Antimicrobial Chemotherapy and Infectious Diseases and Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact